Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 245-254

  Goteti, Kosalaram ^a   Garner, C Edwin ^a   Utley, Lucas ^a   Dai, Jing ^a   Ashwell, Susan ^a   Moustakas, Demetri T ^a   Gönen, Mithat ^b   Schwartz, Gary K ^b   Kern, Steven E ^c   Zabludoff, Sonya ^a   Brassil, Patrick J ^a  

^a ASTRAZENECA   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Combination therapy; PK PD; Tumor growth; Xenograft mice

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 7762; FLAVOPIRIDOL; IRINOTECAN; UNCLASSIFIED DRUG; 3 (CARBAMOYLAMINO) 5 (3 FLUOROPHENYL) N (3 PIPERIDYL)THIOPHENE 2 CARBOXAMIDE; 3-(CARBAMOYLAMINO)-5-(3-FLUOROPHENYL)-N-(3-PIPERIDYL)THIOPHENE-2-CARBOXAMIDE; CAMPTOTHECIN; DRUG DERIVATIVE; FLAVONOID; GROWTH INHIBITOR; PIPERIDINE DERIVATIVE; THIOPHENE DERIVATIVE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STEADY STATE; TUMOR GROWTH; TUMOR VOLUME; ALGORITHM; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENE; HUMAN; METHODOLOGY; NUDE MOUSE; PREDICTION AND FORECASTING; STATISTICAL MODEL; STATISTICS;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FLAVONOIDS; GENES, CDC; GROWTH INHIBITORS; HUMANS; MICE; MICE, NUDE; MODELS, STATISTICAL; NEOPLASM TRANSPLANTATION; PIPERIDINES; PREDICTIVE VALUE OF TESTS; THIOPHENES; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953057864     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1153-z     Document Type: Article

References (22)

1. Food and Drug Administration (2004) Innovation: stagnation: challenge and opportunity on the critical path to new medical product 2004
2. Bergstrom M, Monazzam A, Razifar P, Ide S, Josephsson R, Langstrom B (2008) Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVPAUY922. J Nucl Med 49:1204-1210
3. Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, Jang SH, Kenna L, Lesko LJ, Madabushi R, Men Y, Powell JR, Qiu W, Ramchandani RP, Tornoe CW, Wang Y, Zheng JJ (2007) Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 81:213-221
4. Dundr M, Hoffmann-Rohrer U, Hu Q, Grummt I, Rothblum LI, Phair RD, Misteli T (2002) A kinetic framework for a mammalian RNA polymerase in vivo. Science 298:1623-1626
5. Gobburu JV, Sekar VJ (2002) Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. Int J Clin Pharmacol Ther 40:281-288
6. Goteti K, Brassil PJ, Good SS, Garner CE (2008) Estimation of human drug clearance using multiexponential techniques. J Clin Pharmacol 48:1226-1236
7. Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P (1998) Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 42:165-170
8. Janetka JW, Almeida L, Ashwell S, Brassil PJ, Daly K, Deng C, Gero T, Glynn RE, Horn CL, Ioannidis S, Lyne P, Newcombe NJ, Oza VB, Pass M, Springer SK, Su M, Toader D, Vasbinder MM, Yu D, Yu Y, Zabludoff SD (2008) Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. Bioorg Med Chem Lett 18(14):4242-4248
9. Janetka JW, Ashwell S, Zabludoff S, Lyne P (2007) Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Devel 10:473-486
10. Magni P, Simeoni M, Poggesi I, Rocchetti M, De Nicolao G (2006) A mathematical model to study the effects of drugs administration on tumor growth dynamics. Math Biosci 200:127-151
11. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK (2001) Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 7:4209-4219
12. Powell JR, Gobburu JV (2007) Pharmacometrics at FDA: evolution and impact on decisions. Clin Pharmacol Ther 82:97-102
13. Rocchetti M, Poggesi I, Germani M, Fiorentini F, Pellizzoni C, Zugnoni P, Pesenti E, Simeoni M, De Nicolao G (2005) A pharmacokinetic-pharmacodynamic model for predicting tumour growth inhibition in mice: a useful tool in oncology drug development. Basic Clin Pharmacol Toxicol 96:265-268
14. Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I (2007) Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 43:1862-1868
15. Schwartz GK (2005) Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 23:4499-4508
16. Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK (2005) A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 11:3836-3845
17. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101
18. Sung JH, Dhiman A, Shuler ML (2009) A combined pharmacokinetic- pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration. J Pharm Sci 98:1885-1904
19. Wang S, Guo P, Wang X, Zhou Q, Gallo JM (2008) Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther 7:407-417
20. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T (2008) Pharmacokinetic- pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267-1274
21. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7:2955-2966
22. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JH, Huitema AD (2008) PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83:829-839